Comprehensive Stock Comparison
Compare Theriva Biologics, Inc. (TOVX) vs BiomX Inc. (PHGE) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  TOVX | Beta 0.80 vs PHGE's 0.93, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) |  PHGE | -48.8% vs TOVX's -86.1% |
| Efficiency (ROA) | TOVX | -84.9% ROA vs PHGE's -142.8%, ROIC -142.7% vs -305.2% |
Who Each Stock Is For
Income & stability
TOVXbeta 0.80
Growth exposure
PHGEEPS growth 71.2%
Long-term compounding (10Y)
PHGE-99.7% 10Y total return vs TOVX's -100.0%
Sleep-well-at-night portfolio
TOVXLower volatility, beta 0.80, Low D/E 8.2%, current ratio 2.15x
Defensive / Recession hedge
TOVXBeta 0.80, current ratio 2.15x
Business Model
What each company does and how it makes money
Theriva Biologics is a clinical-stage biopharmaceutical company developing novel therapeutics for diseases with high unmet medical need, particularly in oncology and gastrointestinal disorders. It generates revenue primarily through research collaborations and licensing agreements — though as a pre-revenue clinical-stage company, it currently relies on equity financing and grants to fund operations. The company's competitive advantage lies in its proprietary platform technologies for developing targeted biologics and its focus on niche therapeutic areas where existing treatments are inadequate.
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
TOVX 2PHGE 1TOVX1/1 metricsTOVX6/8 metricsPHGE6/6 metricsTOVX leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). PHGE leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
TOVX and PHGE operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | TOVXTheriva Biologics… | PHGEBiomX Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$26M | -$6M |
| Net IncomeAfter-tax profit | -$26M | -$37M |
| Free Cash FlowCash after capex | -$19M | -$28M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +93.4% | -6.5% |
Valuation Metrics
| Metric | TOVXTheriva Biologics… | PHGEBiomX Inc. |
|---|---|---|
| Market CapShares × price | $252,100 | $82.8B |
| Enterprise ValueMkt cap + debt − cash | -$10M | $82.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | -4.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 0.01x | 3427.64x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
PHGE delivers a -3.6% return on equity — every $100 of shareholder capital generates $-4 in annual profit, vs $-4 for TOVX. TOVX carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHGE's 0.40x. On the Piotroski fundamental quality scale (0–9), PHGE scores 3/9 vs TOVX's 1/9, reflecting mixed financial health.
| Metric | TOVXTheriva Biologics… | PHGEBiomX Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -3.9% | -3.6% |
| ROA (TTM)Return on assets | -84.9% | -142.8% |
| ROICReturn on invested capital | -142.7% | -3.1% |
| ROCEReturn on capital employed | -69.1% | -159.9% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.08x | 0.40x |
| Net DebtTotal debt minus cash | -$10M | -$8M |
| Cash & Equiv.Liquid assets | $12M | $18M |
| Total DebtShort + long-term debt | $2M | $10M |
| Interest CoverageEBIT ÷ Interest expense | — | -36.86x |
Total Returns (with DRIP)
A $10,000 investment in PHGE five years ago would be worth $47 today (with dividends reinvested), compared to $14 for TOVX. Over the past 12 months, PHGE leads with a -48.8% total return vs TOVX's -86.1%. The 3-year compound annual growth rate (CAGR) favors PHGE at -59.1% vs TOVX's -79.4% — a key indicator of consistent wealth creation.
| Metric | TOVXTheriva Biologics… | PHGEBiomX Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -28.1% | +194.4% |
| 1-Year ReturnPast 12 months | -86.1% | -48.8% |
| 3-Year ReturnCumulative with dividends | -99.1% | -93.2% |
| 5-Year ReturnCumulative with dividends | -99.9% | -99.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -79.4% | -59.1% |
Risk & Volatility
TOVX is the less volatile stock with a 0.80 beta — it tends to amplify market swings less than PHGE's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PHGE currently trades 42.8% from its 52-week high vs TOVX's 12.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TOVXTheriva Biologics… | PHGEBiomX Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.80x | 0.93x |
| 52-Week HighHighest price in past year | $1.50 | $14.71 |
| 52-Week LowLowest price in past year | $0.16 | $1.56 |
| % of 52W HighCurrent price vs 52-week peak | +12.5% | +42.8% |
| RSI (14)Momentum oscillator 0–100 | 47.8 | 51.0 |
| Avg Volume (50D)Average daily shares traded | 11.6M | 1.3M |
Analyst Outlook
| Metric | TOVXTheriva Biologics… | PHGEBiomX Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Theriva Biologics, … (TOVX) | 100 | 0.18 | -99.8% |
| BiomX Inc. (PHGE) | 100 | 0.23 | -99.8% |
BiomX Inc. (PHGE) returned -100% over 5 years vs Theriva Biologics, … (TOVX)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Theriva Biologics, … (TOVX) | $0.00 | $0.00 | — |
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
Theriva Biologics, Inc.'s revenue grew from $0M (2015) to $0M (2024) — a 0.0% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Theriva Biologics, … (TOVX) | -189.68 | -19.03 | +90.0% |
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
Theriva Biologics, Inc.'s EPS grew from $-189.68 (2015) to $-19.03 (2024).
Chart 4Free Cash Flow — 5 Years
Theriva Biologics, Inc. generated $-17M FCF in 2024 (-31% vs 2021). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).
TOVX vs PHGE: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — TOVX or PHGE?
Over the past 5 years, BiomX Inc. (PHGE) delivered a total return of -99.5%, compared to -99.9% for Theriva Biologics, Inc. (TOVX). A $10,000 investment in PHGE five years ago would be worth approximately $47 today (assuming dividends reinvested). Over 10 years, the gap is even starker: PHGE returned -99.7% versus TOVX's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — TOVX or PHGE?
By beta (market sensitivity over 5 years), Theriva Biologics, Inc. (TOVX) is the lower-risk stock at 0.80β versus BiomX Inc.'s 0.93β — meaning PHGE is approximately 16% more volatile than TOVX relative to the S&P 500. On balance sheet safety, Theriva Biologics, Inc. (TOVX) carries a lower debt/equity ratio of 8% versus 40% for BiomX Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — TOVX or PHGE?
Theriva Biologics, Inc. (TOVX) is the more profitable company, earning 0.0% net margin versus 0.0% for BiomX Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TOVX leads at 0.0% versus 0.0% for PHGE. At the gross margin level — before operating expenses — TOVX leads at 0.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — TOVX or PHGE?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is TOVX or PHGE better for a retirement portfolio?
For long-horizon retirement investors, Theriva Biologics, Inc. (TOVX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.80)). Both have compounded well over 10 years (TOVX: -100.0%, PHGE: -99.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between TOVX and PHGE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.